ABSTRACT
We present an unusual case of a 60 year old male who was noted to have primary hypothyroidism and decreased consciousness which did not respond to Levothyroxine. Further investigations revealed a diagnosis of Hashimoto's Encephalopathy which responded well to steroids. We describe the case in detail and discuss the available relevant literature on this topic.
Subject(s)
Brain Diseases/complications , Brain Diseases/diagnosis , Consciousness , Hashimoto Disease/complications , Hashimoto Disease/diagnosis , Hypothyroidism/complications , Hypothyroidism/diagnosis , Thyroxine/therapeutic use , Brain Diseases/drug therapy , Diagnosis, Differential , Electroencephalography/methods , Encephalitis , Glucocorticoids/therapeutic use , Hashimoto Disease/drug therapy , Humans , Hypothyroidism/drug therapy , Male , Methylprednisolone/therapeutic use , Middle Aged , Treatment OutcomeABSTRACT
BACKGROUND: Orlistat has been shown to increase adiponectin and reduce progression to type 2 diabetes in obese Caucasians. Some effects of orlistat are thought to be independent of weight loss by altering gut flora and the production of endotoxin lipopolysaccharide (LPS). We studied the effect of dietary treatment with and without orlistat in South Asian individuals with impaired glucose tolerance (IGT) on adiponectin and inflammatory markers including LPS. METHODS: South Asian individuals were randomised to either dietary treatment with orlistat or dietary treatment alone. At the end of 12 months, a comparison was made between the two groups for differences in anthropomorphic measurements and serum markers. RESULTS: Three hundred and five individuals underwent oral glucose tolerance test of whom 40 had IGT. Complete baseline and 1-year data was available for 31 patients. After 1 year, patients in the orlistat group demonstrated a greater but insignificant decrease in weight (4.5 +/- 0.1 kg), and a significant increase in adiponectin (6.73 +/- 3.2 microg/ml) and decrease in LPS (4.55 +/- 1.98 EU/ml) compared with- the diet-alone group. In the orlistat group the reduction in LPS was correlated with the increase in adiponectin (p < 0.005). CONCLUSION: The increase in adiponectin levels in the orlistat group would suggest that orlistat may reduce the progression to type 2 diabetes in South Asian individuals by raising serum adiponectin. The finding that LPS levels are also reduced by orlistat and that this reduction correlates with the increase in adiponectin raises the possibility that the increase in adiponectin may be mediated via an effect on LPS levels.
Subject(s)
Adipokines/blood , Glucose Intolerance/drug therapy , Lactones/therapeutic use , Lipopolysaccharides/blood , Adult , Combined Modality Therapy , Female , Follow-Up Studies , Glucose Intolerance/blood , Glucose Intolerance/diet therapy , Humans , Lipids/blood , Male , OrlistatABSTRACT
A popular hypothesis for the greater prevalence of type 2 diabetes and cardiovascular disease in UK south Asians is that they have an increased susceptibility of developing insulin resistance in response to certain environmental factors, including obesity and adoption of a sedentary lifestyle. Insulin resistance is postulated as a central feature of the metabolic syndrome, culminating in type 2 diabetes, atherosclerotic vascular disease and CHD; a pathway potentially accelerated by migration/urbanisation. We describe and compare the prevalence of type 2 diabetes, cardiovascular disease and their associated risk factors in UK south Asian and white Caucasian populations to determine possible reasons for the increased preponderance of these diseases in south Asians, and highlight key evidence for optimal risk factor management. Finally, we describe a UK community-based programme that attempts to reduce the morbidity and mortality from type 2 diabetes and cardiovascular disease in south Asians through a new approach to management.
Subject(s)
Asian People/statistics & numerical data , Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Diabetic Angiopathies/epidemiology , Adult , Age Distribution , Diabetes Mellitus, Type 2/genetics , Diabetic Angiopathies/genetics , Genetic Predisposition to Disease , Humans , Middle Aged , Prevalence , Risk Factors , United Kingdom/epidemiologyABSTRACT
We present a case of a 29-year-old woman with known Type 1 diabetes who presented with diabetic ketoacidosis (DKA). Despite appropriate treatment and initial improvement, 12 h after initiation of treatment she deteriorated rapidly and developed pulmonary oedema, cerebral oedema and multiple infarctions of the brain and cervical spinal cord. This resulted in spastic quadraparesis and she has remained wheelchair-bound. These complications of DKA are rare and unpredictable. In this case report we discuss the proposed aetiologies of these complications with reference to our case report and highlight the importance of vigilance for early signs of these complications during the treatment of all patients with DKA.
Subject(s)
Brain Edema/complications , Brain Infarction/complications , Diabetic Ketoacidosis/complications , Pulmonary Edema/complications , Spinal Cord/blood supply , Adult , Cervical Vertebrae , Diabetes Mellitus, Type 1/complications , Female , Humans , Infarction/complications , Quadriplegia/etiologyABSTRACT
A 24 year old white woman presented with sudden onset of flaccid quadriparesis and hypokalaemia. She was later found to be thyrotoxic. Paralysis resolved with potassium supplements, and after initiation of antithyroid medication she had no further episodes of hypokalaemic paralysis. To the best of the authors' knowledge, and after a Medline search, thyrotoxic periodic paralysis has not been described previously in a white woman.
